C. Forray

发表

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder

P. Verbanck, Y. Lecrubier, S. Kasper, 2010, International clinical psychopharmacology.

Perspectives for an Integrated Biomarker Approach to Drug Discovery and Development

C. Swanson, S. Rabacchi, I. Antonijevic, 2008 .

Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression

A. Serretti, Y. Lecrubier, S. Kasper, 2012, Neuropsychobiology.

In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist.

M. Bock, R. Chang, B. Lagu, 2000, European journal of pharmacology.

The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

T. Branchek, H. Lepor, E. Shapiro, 1994, Molecular pharmacology.

4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.

M. Bock, R. Chang, M. Patane, 1998, Journal of medicinal chemistry.

Stimulation of arachidonic acid release and eicosanoid biosynthesis in an interleukin 2-dependent T cell line.

R. Abraham, C. Forray, G. Shipley, 1986, Journal of immunopharmacology.

A convenient synthesis of 2-amino-2-oxazolines and their pharmacological evaluation at cloned human α adrenergic receptors

T. Branchek, Diana Wang, P. Vaysse, 1994 .

Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study

S. Potkin, D. Naber, P. Hertel, 2017, Schizophrenia Research.

Aripiprazole Once-monthly is Superior to Paliperidone Palmitate in a Randomized, Head-to-head Clinical Study

S. Potkin, D. Naber, P. Hertel, 2015, European psychiatry.

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

J. Barrow, R. Freidinger, R. Chang, 2000, Bioorganic & medicinal chemistry letters.

Complex allosteric modulation of cardiac muscarinic receptors by protamine: potential model for putative endogenous ligands.

C. Forray, E. El-Fakahany, J. Hu, 1992, Molecular pharmacology.

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY

S. Potkin, D. Naber, P. Hertel, 2017, International clinical psychopharmacology.

Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist

B. Borowsky, T. Branchek, T. Blackburn, 2002, Nature Medicine.

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression

A. Serretti, S. Kasper, J. Mendlewicz, 2012, Neuroscience Letters.

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension

O. Howes, J. Kane, P. Hertel, 2022, Schizophrenia Research.

In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

J. Barrow, K. Rittle, R. Freidinger, 2000 .

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.

R. Chang, P. Kling, B. Lagu, 1999, Journal of medicinal chemistry.

Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective alpha1a-adrenergic receptor antagonists.

R. Chang, B. Lagu, C. Forray, 2000, Bioorganic & medicinal chemistry letters.

Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist

Beth Borowsky, B. Borowsky, T. Branchek, 2002, Nature Medicine.

Design and Synthesis of Novel α1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia

R. Chang, T. Branchek, C. Forray, 1998 .

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series.

R. Chang, P. Kling, B. Lagu, 1999, Journal of medicinal chemistry.

De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.

A. D. Rodrigues, R. Chang, B. Lagu, 2000, Journal of medicinal chemistry.

Neurotensin Stimulates Inositol Phospholipid Metabolism and Calcium Mobilization in Murine Neuroblastoma Clone N1E‐115

E. Richelson, C. Forray, R. Snider, 1986, Journal of neurochemistry.

Agonist‐induced down‐regulation of m1 muscarinic receptors and reduction of their mRNA level in a transfected cell line

C. Forray, E. El-Fakahany, J. Hu, 1990, FEBS letters.

Role of intracellular Ca2+ mobilization in muscarinic and histamine receptor-mediated activation of guanylate cyclase in N1E-115 neuroblastoma cells: assessment of the arachidonic acid release hypothesis.

C. Forray, E. El-Fakahany, W. Surichamorn, 1990, Molecular pharmacology.

Glucocorticoids Potentiate the Prostaglandin E1‐Mediated Cyclic AMP Formation by a Cultured Murine Neuroblastoma Clone

E. Richelson, C. Forray, 1985, Journal of neurochemistry.

Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF*

B. Borowsky, T. Branchek, J. A. Bonini, 2000, The Journal of Biological Chemistry.

Subneuronal Fate of Intracerebroventricular Injected 3H‐Melatonin

C. Forray, B. G. Ortega-Corona, F. Antón‐Tay, 1988, Journal of pineal research.

Expression Cloning of a Rat Hypothalamic Galanin Receptor Coupled to Phosphoinositide Turnover*

T. Branchek, D. Linemeyer, C. Gerald, 1997, The Journal of Biological Chemistry.

The presence of an M4 subtype muscarinic receptor in the bovine adrenal medulla revealed by mRNA and receptor binding analyses.

C. Forray, E. El-Fakahany, J. Fernando, 1991, European journal of pharmacology.

Inhibition of cyclic AMP formation in N1E-115 neuroblastoma cells is mediated by a non-cardiac M2 muscarinic receptor subtype

C. Forray, E. El-Fakahany, W. Surichamorn, 1989, Brain Research.

Neurotransmitter receptors mediate cyclic GMP formation by involvement of arachidonic acid and lipoxygenase.

E. Richelson, C. Forray, M. Mckinney, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Challenges and opportunities for the development of new antipsychotic drugs.

C. Forray, R. Buller, 2017, Biochemical pharmacology.

Different mechanisms of antagonism by methoctramine of two neuronal muscarinic receptor-mediated second messenger responses.

A. Fryer, C. Forray, E. El-Fakahany, 1989, The Journal of pharmacology and experimental therapeutics.

A solubility shift occurs during depletion-transformation of prolactin within the lactating rat pituitary.

C. Forray, F. Mena, C. Clapp, 1982, Endocrinology.

Characterization of the striatal M2 muscarinic receptor mediating inhibition of cyclic AMP using selective antagonists: a comparison with the brainstem M2 receptor.

D. Anderson, C. Forray, M. Mckinney, 1989, The Journal of pharmacology and experimental therapeutics.

Methoctramine, a cardioselective muscarinic antagonist, stimulates phosphoinositide hydrolysis in rat cerebral cortex.

C. Forray, E. El-Fakahany, N. H. Lee, 1989, European journal of pharmacology.

Localization of the alpha 1A-adrenoceptor in the human prostate.

H. Lepor, E. Shapiro, C. Forray, 1995, The Journal of urology.

Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System*

B. Borowsky, T. Branchek, J. A. Bonini, 2000, The Journal of Biological Chemistry.

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate

S. Potkin, D. Naber, P. Hertel, 2016, The international journal of neuropsychopharmacology.

The MCH receptor family: feeding brain disorders?

C. Forray, 2003, Current opinion in pharmacology.

On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.

C. Forray, E. El-Fakahany, 1990, Molecular pharmacology.

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study

S. Potkin, D. Naber, P. Hertel, 2017, PloS one.

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia

S. Potkin, D. Naber, P. Hertel, 2015, Schizophrenia Research.

No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression

Julien Mendlewicz, Siegfried Kasper, Alessandro Serretti, 2011, Psychiatry Research.

Design and synthesis of novel dihydropyridine alpha-1a antagonists.

R. Chang, C. Forray, W. Wong, 1999, Bioorganic & medicinal chemistry letters.

Receptor-mediated generation of an EDRF-like intermediate in a neuronal cell line detected by spin trapping techniques.

C. Arroyo, C. Forray, G. Rosen, 1990, Biochemical and biophysical research communications.

Activation of cyclic GMP formation in mouse neuroblastoma cells by a labile nitroxyl radical. An electron paramagnetic resonance/spin trapping study.

C. Arroyo, C. Forray, 1991, European journal of pharmacology.

Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes.

T. Branchek, M. Michel, C. Forray, 1993, Molecular pharmacology.

The rat homologue of the bovine alpha 1c-adrenergic receptor shows the pharmacological properties of the classical alpha 1A subtype.

T. Branchek, R. Weinshank, P. Vaysse, 1994, Molecular pharmacology.

Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.

T. Branchek, L. Borden, C. Forray, 1995, Journal of medicinal chemistry.

Design and Synthesis of an α1a‐Adrenergic Receptor Subtype‐Selective Antagonist from BE2254

C. Forray, C. Gluchowski, G. Chiu, 2006, Chemical Biology and Drug Design.

Identification of a dihydropyridine as a potent alpha1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate.

T. Branchek, H. Lepor, P. Vaysse, 1998, Journal of medicinal chemistry.

Modeling and mutagenesis of the human alpha 1a-adrenoceptor: orientation and function of transmembrane helix V sidechains.

T. Branchek, H. Nakanishi, D. Craig, 1996, Receptors & channels.

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.

J. Barrow, K. Rittle, R. Freidinger, 2000, Journal of medicinal chemistry.

A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression.

A. Serretti, Y. Lecrubier, S. Kasper, 2011, Journal of affective disorders.

Relationship between the partial inhibition of muscarinic receptor-mediated phosphoinositide hydrolysis by phorbol esters and tetrodotoxin in rat cerebral cortex.

C. Forray, E. El-Fakahany, E. A. Abdallah, 1990, Brain research. Molecular brain research.

Lack of intrinsic activity and significant subtype selectivity of SR 95639A at muscarinic receptors.

C. Forray, E. El-Fakahany, A. Mohamed, 1992, European journal of pharmacology.

Pharmacological evaluation of UK-14,304 analogs at cloned human α adrenergic receptors

T. Branchek, P. Vaysse, C. Forray, 1995 .

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder

Y. Lecrubier, S. Kasper, J. Mendlewicz, 2011, International clinical psychopharmacology.

Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes

Y. Lecrubier, S. Kasper, J. Mendlewicz, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

2-amino-2-oxazolines as subtype selective alpha(2) adrenoceptor agonists.

T. Branchek, P. Vaysse, C. Forray, 2000, Journal of medicinal chemistry.

COMT and age at onset in mood disorders: A replication and extension study

A. Serretti, S. Kasper, J. Mendlewicz, 2011, Neuroscience Letters.

Effects of tacrine on brain muscarinic-receptor-mediated second-messenger signals.

C. Forray, E. El-Fakahany, N. H. Lee, 1993, Pharmacology.